Physician profile
Michael E Zionts
NPI 1922095249
$15,519.94
in general payments reported to CMS, 2019-2025
11 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,416 · 2020: $6,875 · 2021: $5,827 · 2023: $63.65 · 2024: $173 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388 · Education: $14.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $387.96 |
| Education | $14.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,435.33 | 2019-2021 | |
| Organon LLC | $4,137.36 | 2021 | |
| Janssen Pharmaceuticals, INC | $199.36 | 2021 | |
| Galderma Laboratories, L.P. | $166.76 | 2023-2024 | |
| Stryker Corporation | $148.33 | 2025 | Gamma |
| Astrazeneca Pharmaceuticals LP | $115.69 | 2021 | |
| Acadia Pharmaceuticals INC | $115.23 | 2019 | |
| Indivior INC. | $115.01 | 2019 | |
| Abbvie INC. | $38.33 | 2023 | |
| Pfizer INC. | $31.43 | 2024-2025 | |
| Gilead Sciences, INC. | $17.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zionts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.